| Organovo Holdings is a biotechnology company that focuses on building 3D tissues that recapitulate primary aspects of human disease. Co. uses these models to identify gene targets responsible for driving the disease and initiates drug discovery programs around these validated targets. Co.'s NovoGen Bioprinters® are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Co.'s NovoGen Bioprinters® can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Co.'s NovoGen Bioprinters® also serve as components of its tissue prototyping and manufacturing platform. We show 52 historical shares outstanding datapoints in our coverage of ONVO's shares outstanding history.
Understanding the changing numbers of ONVO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ONVO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ONVO by allowing them to research ONVO shares outstanding history
as well as any other stock in our coverage universe.